Navigation Links
Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
Date:4/5/2011

inances in general, as well as risks and uncertainties associated with the Company's VMAT2 program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's VMAT2 program include, but are not limited to; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate partners for development, commercial manufacturing and marketing and sales activities for the Company's partnered programs; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2010. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
2. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
3. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
4. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
5. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
6. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
8. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
9. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
10. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
11. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Lyme Research Alliance (LRA), ... research at universities, today announced the awarding of seven ... treatment and cure for Lyme and other tick-borne diseases. ... applications in its history—over 20 grant proposals—a 100 percent ... pleased to receive so many solid applications from talented ...
(Date:9/30/2014)... On September 11, Pharma IQ conducted an ... of a session that he will lead on “Stem Cells” ... February 17-18, 2015 in London. In the interview posted ... Sherley to respond to several questions on the current state ... stem cell toxicity, and future trends in the use of ...
(Date:9/30/2014)... Canada (PRWEB) September 30, 2014 Back in ... on 500 square feet. per employee, which included space for ... back then.” says Jeff Howell, partner at Nidea Corporate ... firm in Toronto. “By the year 2000, however, 250 ... now seeing that number come down to 175 to 225 ...
(Date:9/29/2014)... of diagnostics today, with imaging techniques like MRI ... NMR (nuclear magnetic resonance) increasing steeply over the ... resolution and quality still limit these techniques because ... is hyperpolarization, which involves injecting the patient with ... the distribution and fate of specific molecules in ...
Breaking Biology Technology:Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3
... Therapeutics, Inc. (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical ... has voluntarily filed a Form 15 with the Securities ... common stock under the Securities and Exchange Act of ... to file periodic and other reports under the Exchange ...
... vaccine is available now for testing worldwide, from Replikins ... the same Replikins peptide technology which provided the surprise ... outbreak/pandemic was on its way ( http://www.replikins.com ... vaccine is its rapid availability; the WHO, CDC and ...
... - SemBioSys Genetics Inc. (TSX:SBS), specializing in the manufacture ... announced that it has reached an agreement with AVAC ... of its Apo AIMilano candidate. AVAC is a private, ... stage commercial businesses that expand Alberta,s value-added industry. , ...
Cached Biology Technology:Arno Therapeutics to Deregister its Common Stock under the Exchange Act 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 3First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide 2SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC 2SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC 3
(Date:9/30/2014)... at the University of California, San Diego, have completed ... using a method that uses the pixels in an ... known as mesh-free simulation. , The researchers, led by ... at the Jacobs School of Engineering at UC San ... method at the CompIMAGE,14 conference in Pittsburgh this month. ...
(Date:9/30/2014)... all have in common? Unlike most eukaryotic multicellular ... diploid, these organisms are all polyploid, meaning they have ... have 3 and 4 sets of chromosomes, respectively, and ... in fact most plant species are polyploid. Polyploidy, or ... but only recently, with the development of molecular tools, ...
(Date:9/30/2014)... LA JOLLAJoseph Ecker, a Salk professor and Howard ... staff scientist, have been named recipients in the ... of Health (NIH) through the BRAIN (Brain Research ... in neuroscience. The grant, announced September 30, provides ... Salk scientists over three years. , The BRAIN ...
Breaking Biology News(10 mins):First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Salk scientists receive $3 million for BRAIN Initiative grant 2
... February 24, 2012; Wiley-Blackwell, the scientific, technical, medical ... Inc., has launched two new interdisciplinary review publications: ... and Signaling . WIREs Developmental Biology ... produce a complex, fully patterned adult organism. Edited by ...
... different molecules in cancer is an effective way to ... the University of California, San Francisco (UCSF) have foundwork ... include drugs like Avastin. The two-target approach, ... as neuroendocrine pancreatic tumors, may have broad application for ...
... new study by the University of California, Berkeley, Wildlife ... for establishing marine protected areas in Madagascar that offers ... no-take zones to areas that would allow fishing. , ... climate, along with dependence on fisheries and marine resources, ...
Cached Biology News:Wiley-Blackwell launches 2 interdisciplinary review titles in developmental and membrane biology 2Cancer therapy more potent when it hits 2 targets 2Cancer therapy more potent when it hits 2 targets 3Study IDs new marine protected areas in Madagascar 2
... Last innovation from Magnetofection technology, SilenceMag ... system available. Simple, rapid and easy ... and non toxic. Specifically designed for ... silencing at very low doses of ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... Fluorescence Test Plate consists of an anodized ... Inert Organic Fluorescent Compounds embedded in polymerized ... on BioTeks FLx800 and Synergy Multi-Detection Readers. ... GLP compliance while reducing the need for ...
... Agarose and SYBR Safe DNA Gel Stain combo offers ... versus buying these same products separately ... ethidium bromide Eliminates risks ... DNA and RNA fragments from 100 bp to >30 ...
Biology Products: